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Aim Traditionally, risk stratification in heart failure (HF) emphasizes assessment of high risk. We aimed to determine if
biomarkers could identify patients with HF at low risk for death or HF rehospitalization.
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Methods
and results
This analysis was a substudy of The Coordinating Study Evaluating Outcomes of Advising and Counselling in Heart
Failure (COACH) trial. Enrolment of HF patients occurred before discharge. We defined low risk as the absence of
death and/or HF rehospitalizations at 180 days. We tested a diverse group of 29 biomarkers on top of a clinical risk
model, with and without N-terminal pro-B-type natriuretic peptide (NT-proBNP), and defined the low risk biomarker
cut-off at the 10th percentile associated with high positive predictive value. The best performing biomarkers together
with NT-proBNP and cardiac troponin I (cTnI) were re-evaluated in a validation cohort of 285 HF patients. Of
592 eligible COACH patients, the mean (± SD) age was 71 (±11) years and median (IQR) NT-proBNP was
2521 (1301–5634) pg/mL. Logistic regression analysis showed that only galectin-3, fully adjusted, was significantly
associated with the absence of events at 180 days (OR 8.1, 95% confidence interval 1.06–50.0, P= 0.039). Galectin-3,
showed incremental value when added to the clinical risk model without NT-proBNP (increase in area under the
curve from 0.712 to 0.745, P= 0.04). However, no biomarker showed significant improvement by net reclassification
improvement on top of the clinical risk model, with or without NT-proBNP. We confirmed our results regarding
galectin-3, NT-proBNP, and cTnI in the independent validation cohort.
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Conclusion We describe the value of various biomarkers to define low risk, and demonstrate that galectin-3 identifies HF patients
at (very) low risk for 30-day and 180-day mortality and HF rehospitalizations after an episode of acute HF. Such
patients might be safely discharged.
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Keywords Heart failure • Prognosis • Biomarker • N-terminal pro-B-type natriuretic peptide •
Galectin-3 • Risk stratification
Introduction
Heart failure (HF) has significant clinical impact and leads to con-
siderable costs; in the United Kingdom, estimated hospitalization
costs exceed £716 million per year.1 While the overall mortality
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.. rate after acute heart failure (AHF) has decreased in the past two
decades, the number of survivors requiring rehospitalization owing
to HF after an initial admission have risen steadily.2,3 Not only are
readmissions associated with higher costs, they imply an overall
worse prognosis. Patients with four or more AHF readmissions
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have a mortality risk exceeding 40% in the subsequent 6months,
and a median survival of 0.6months after the fourth readmission.4
The extent of this problem is apparent from a recent analysis of
nearly 12 million Medicare beneficiaries,3 where HF was the num-
ber one cause of 30-day rehospitalization, occurring in 25% of all
HF cases and representing 7.6% of all 30-day rehospitalizations.
Consequently, the ability to identify a population of HF patients
at low risk of early revisits and mortality could be beneficial,
allowing early and safe discharge of a selected group with such
low risk. In addition, the remaining population could be targeted
for more aggressive therapy, thus decreasing their probability of
short-term HF rehospitalization as well.
Multiple clinical predictions models with a wide variety of
variables have been developed5–7 to adequately predict either
mortality, HF rehospitalization or a composite of mortality and
HF rehospitalization. However, most prediction models identify
high-risk patients. The absence of high risk is not sufficient to
predict patients who are at low-risk for these endpoints. Biomark-
ers are commonly used in HF,8,9 but biomarkers that identify
patients at high risk, such as troponin,10 B-type natriuretic pep-
tide (BNP),11 blood urea nitrogen (BUN), and creatinine12 do
not—when present at low levels—necessarily identify a cohort
at low risk. Therefore, for this analysis, our purpose was to eval-
uate a large panel of diverse biomarkers to identify a cohort at
low short-term risk for mortality and/or HF rehospitalization after
hospital discharge for HF.
Methods
Derivation cohort
The Coordinating Study Evaluating Outcomes of Advising and
Counselling in Heart Failure (COACH)13 trial was a multicentre, ran-
domized, controlled study in which 1023 patients were enrolled after
hospitalization because of acutely decompensated HF. Patients were
assigned to one of three groups: a control group (follow-up by a cardi-
ologist) and two intervention groups with additional basic or intensive
support by a nurse specializing in management of patients with HF.
Patients were studied for 18 months.14,15 From this data set, we anal-
ysed the mortality and HF rehospitalization rates of 592 patients after
hospital discharge for low-risk predictors of death or rehospitalization.
Of these 592 patients plasma was available, as previously published,16
and baseline characteristics were fully comparable to the complete
COACH cohort (data not shown). Blood samples were collected at
study enrolment, this was for the COACH study at discharge. Patients
were hospitalized for 13 days (±10) after admission with AHF.
Validation cohort
The Translational Initiative on Unique and novel strategies for
Management of Patients with Heart Failure (TRIUMPH; NTR1893;
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1893,
N= 478) trial was a multicentre, observational trial, which aimed
to identify and validate potentially clinically important biomarkers in
patients admitted to the hospital with a diagnosis of AHF. Inclusion
criteria of the TRIUMPH trial were age ≥18 years, admitted with the
diagnosis of AHF increased N-terminal pro-B-type natriuretic peptide ..
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.. (NT-proBNP) levels, treated with diuretics and evidence of left ven-
tricular dysfunction. Patients were excluded when HF was caused by a
non-cardiac condition, severe valvular dysfunction, or an acute cardiac
syndrome, had a planned coronary intervention, were on the cardiac
transplantation list, received haemodialysis, or had a non-cardiac con-
dition associated with a life expectancy of less than 1 year. The primary
endpoint was the composite of cardiovascular death, left ventricular
assist device implantation, heart transplantation or rehospitalization
for the management of acute HF. From this data set, we analysed
the mortality and HF rehospitalization rates of 285 patients after
hospital discharge from whom only galectin-3, NT-proBNP, and cTnI
levels were available. Blood sampling in both studies was performed at
hospital discharge, providing the best prognostic value for NT-proBNP.
These studies and the current analyses have been performed conform
the Declaration of Helsinki; both study protocols, were reviewed and
approved by the local Institutional Review Board, and all study subjects
provided written informed consent.
End points
The primary outcome for the present analyses was the absence of
all-cause mortality and/or HF rehospitalization after 180 days. Sec-
ondary outcomes were the absence of all-cause mortality and/or HF
rehospitalization at 30, 90 and 365 days. An independent end-point
committee adjudicated all endpoints.13,17
Biochemical measurements
Biomarker analyses were performed using the following commercial
assays: C-reactive protein (CRP), pentraxin-3, growth differentiation
factor 15 (GDF-15), myeloperoxidase (MPO), syndecan-1, periostin,
tumour necrosis factor alpha receptor 1a (TNF𝛼R1a), osteopon-
tin, receptor of advanced glycation end-products (RAGE), angiogenin,
endothelial cell-selective adhesion molecule (ESAM), D-dimer, pros-
aposin B (PSAP-B), BNP, Troy, supression of tumorigenicity 2 ST-2, neu-
ropilin, mesothelin, polymeric immunoglobulin receptor 1 (PIGR-1),
cystatin C, and neutrophil gelatinase-associated lipocalin (NGAL) were
measured by Alere San Diego, Inc. (San Diego, CA, USA) using com-
petitive enzyme-linked immunosorbent assays (ELISAs) on a Luminex®
platform. Galectin-3 plasma levels were measured using a commer-
cial enzyme-linked immunosorbent assay (BG Medicine, Waltham,
MA, USA).18,19 Transforming growth factor-beta (TGF-𝛽) and vascular
endothelial growth factor (VEGF) were analysed by SearchLight® pro-
teome arrays (Aushon BioSystems, Billerica, MA, USA) using a quantita-
tive multiplexed sandwich ELISA system. The NT-proBNP concentra-
tion was measured by using the Elecsys proBNP ELISA (Roche Diagnos-
tics, Mannheim, Germany). Erythropoietin alpha (EPO) was measured
using the immulite® EPO ELISA (Diagnostic Products Corporation,
Los Angeles, CA, USA). Cardiac troponin I (cTnI) and interleukin-6
(IL-6) were measured using highly sensitive single molecule counting
(SMCTM) technology (RUO, Erenna Immunoassay System; Singulex Inc.,
Alameda, CA, USA). The intra- and inter-assay coefficients of variation
of each biomarker is presented in the Supplementary material online,
Table S1. The Modification of Diet in Renal Disease (MDRD) formula
was used to estimate glomerular filtration rate (eGFR).
Statistical analyses
Baseline characteristics are presented as means and standard devia-
tions (SDs), or medians and interquartile ranges (IQRs), as appropriate.
© 2015 The Authors
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To determine the optimal biomarker cut point for predicting low risk,
we performed a sensitivity analysis, exploring different values of var-
ious biomarkers. We used the 10th, 20th, and 30th decile values
of all biomarkers studied in COACH, a cut point at the 10th per-
centile was found to provide most optimal sensitivity and still selected
enough patients to be clinically relevant. We expanded our sensitiv-
ity analysis with the best-performing biomarkers over the complete
range of percentiles (5th–95th). In the primary analysis, all biomark-
ers were ranked based upon positive predictive value (PPV). Logistic
regression analysis (univariable, and multivariable analyses) was used
to generate estimates of odds ratios and 95% CIs associated with
the four best-performing biomarkers, and commonly used biomark-
ers (NT-proBNP and cTnI), as dichotomized values. Consistent with
previous studies,20,21 we adjusted in a multivariable analysis first for
age and sex, then second for a clinical model that has been pub-
lished (the COACH risk engine),22 with the further addition of the
duration of hospitalization. The COACH risk engine consists of the
following parameters: age, sex, diastolic blood pressure, pulse pres-
sure, stroke, myocardial infarction, atrial fibrillation, peripheral arterial
disease, diabetes, left ventricle ejection fraction, previous HF hospi-
talization, serum sodium, serum creatinine, and the biomarker plasma
NT-proBNP. As this analysis aimed to describe the value of biomarkers,
and as NT-proBNP is a biomarker, we present the results for the vari-
ous biomarkers on top of the clinical risk model (COACH risk engine),
both excluding NT-proBNP (–) and including NT-proBNP (+). To con-
firm our ranking, we performed multiple (×1000) bootstrap runs in
which all the biomarkers and the clinical risk model variables were
entered in a stepwise logistic regression analysis for the absence of
an event, and performed ranking based upon the frequency a variable
was added to the model. Cox proportional hazards regression analy-
ses were performed to adjust for the time to event, using the same
model and biomarkers. Areas under receiver operating characteristic
curves (AUROCs) were derived from the clinical risk model excluding
or including NT-proBNP, and these models plus biomarker (<10th per-
centile and continuously) were compared using the method of deLong
et al.,23 which accounts for the correlated nature of the curves. We
calculated odds ratios for each patient using the clinical risk model
with NT-proBNP, and we divided the population in tertiles (odds ratio
<4.3, 4.4–8.4, >8.5). Notably, a low odds ratio is associated with a high
event rate, while a high odds ratio is associated with a low event rate.
We then we assessed the distribution and event rates of patients with
biomarker levels <10th percentile.
Reclassification indices were assessed using the continuous net
reclassification improvement (NRI) metric and integrated discrimina-
tion improvement (IDI).24
Finally, galectin-3, NT-proBNP, and cTnI were validated using the
TRIUMPH data set. Both PPV and logistic regression analysis were
repeated with the 10th percentile found in TRIUMPH for both
biomarkers. For both analyses, P-values below <0.05 were considered
to denote significant differences. Analyses were performed with STATA
software (version 13.0; Stata Corp, College Station, TX, USA).
Results
Derivation cohort (COACH)
Data from 592 patients were available for the current analyses.
This subset of patients had baseline characteristics that were com-
parable to the entire COACH cohort as reported (N=1023, data
not shown).16 The mean (SD) age was 71 (±11) years, and 227 ..
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.. (38%) patients were female. Median [IQR] NT-proBNP was 2521
[1301–5634] pg/mL and mean ejection fraction was 33% (±14%).
Table 1 displays the baseline characteristics of this population, and
whether or not they endured an event after 180 days.
Biomarkers and prediction
All available biomarkers are displayed in Table 2 ordered by per-
formance (PPV for composite endpoint). For each biomarker,
we report the 10th percentile cut-off value, the sensitivity,
1-specificity, the PPV, and the exact number of events, occurring
within 180 days for patients <10th percentile. For clarity, we
present the exact number of events within 30 days, 90 days, and
1 year in the Supplementary material online, Table S2. Of all
biomarkers evaluated, galectin-3 had the highest PPV to rule out
events (0.983), corresponding with rank 1, while periostin had the
lowest PPV (0.733), resulting in rank 29. The top four biomarkers
were selected (galectin-3, EPO, TNF𝛼R1a, and TGF-𝛽) and con-
sidered for additional analyses. We also evaluated NT-proBNP and
cTnI because these are commonly used in daily clinical practice.
We have also performed all analyses with BNP; this yielded inferior
results compared with NT-proBNP and these data are therefore
not shown. Logistic regression analyses were performed with
these biomarkers as dichotomized values for the absence of an
event within 180 days. After adjustment for age and sex, galectin-3,
EPO and TNF𝛼R1a remained significant predictors of low risk.
After adjusting for the clinical risk model with NT-proBNP, only
galectin-3 remained significant (OR 8.1 [1.06–50], P= 0.039).
No other biomarkers were (univariably) predictive for low risk
(Table 3). Additional sensitivity analyses were performed. First,
consecutive percentile cut-offs for the selected biomarkers were
assessed (Figure 1), and it was observed that galectin-3 has particu-
lar value in the low end with adjusted ORs ranging between 4 and
8. Second, we considered the 10th, 20th, and 30th percentile but
this did not substantially alter the ranking (see the Supplementary
material online, Table S3). Finally, after a 1000 bootstrap runs, EPO
and galectin-3 consistently emerged as top ranked biomarkers for
the 10th and 20th and 30th percentiles (see the Supplementary
material online, Table S4). In the Cox proportional hazard analysis,
which relates to the time that passes before an event occurs using
the same biomarkers and clinical risk model with NT-proBNP,
we observed that only galectin-3 remained significant after full
adjustment (HR 7.69 IQR 1.04–50, P= 0.045; Supplementary
material online, Table S5).
The AUROCs are presented in the Supplementary material
online (Table S6) and no biomarker by itself had a significant
addition to the clinical risk model with NT-proBNP. We observed
that galectin-3 showed incremental value (P= 0.04) on top of the
clinical risk model without NT-proBNP, while the others did not
(including NT-proBNP <10th percentile); the combination of the
top four biomarkers also showed incremental value (P= 0.02). In
addition to the 10th percentile cut-off we also show the AUROCs
for biomarkers when added continuously (see the Supplementary
material online, Table S6).
When considering the tertiles in ORs based upon the clinical risk
model with NT-proBNP, we observed that 30–57% of the patients
© 2015 The Authors
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Table 1 Baseline characteristics of the Coordinating Study Evaluating Outcomes of Advising and Counselling in
Heart Failure (COACH) study and stratified by events at 180days
Characteristics Total (N= 592) No event at 180days (n= 452) Event at 180days (n= 140) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years), mean (SD) 71 (11) 70 (11) 73 (11) 0.003
Female, n (%) 227 (38) 182 (40) 45 (32) 0.084
SBP (mmHg), mean (SD) 118 (21) 119 (21) 115 (20) 0.10
DBP (mmHg), mean (SD) 69 (12) 69 (12) 66 (12) 0.005
Hypertension, n (%) 256 (43) 194 (43) 62 (44) 0.78
BMI (kg/m2), mean (SD) 27 (6) 27 (5) 27 (6) 0.52
Diabetes, n (%) 176 (30) 117 (26) 59 (42) <0.001
Current smoker, n (%) 101 (17) 78 (18) 23 (17) 0.76
Atrial fibrillation, n (%) 270 (46) 197 (44) 73 (52) 0.076
Myocardial infarction, n (%) 239 (40) 170 (38) 69 (49) 0.014
HF history
NYHA
Class I/II, n (%) 279 (47) 232 (51) 47 (34) 0.002
Class III, n (%) 293 (50) 208 (46) 85 (61)
Class IV, n (%) 20 (3) 13 (3) 7 (5)
LVEF (%), mean (SD) 33 (14) 34 (14) 32 (14) 0.22
Treatment
ACEi/ARB, n (%) 486 (82) 376 (83) 110 (79) 0.21
𝛽-Blocker, n (%) 398 (67) 317 (70) 81 (58) 0.007
Loop diuretic, n (%) 567 (96) 431 (95) 136 (97) 0.36
Digoxin, n (%) 190 (32) 142 (31) 48 (34) 0.53
MRA, n (%) 328 (55) 248 (55) 80 (57) 0.64
Laboratory measurements
eGFR (mL/min.1.73m2), mean (SD) 54 (20) 56 (20) 46 (18) <0.001
NT-proBNP (pg/mL), median [IQR] 2521 [1301–5634] 2239 [1170–4576] 4480 [2131–11318] <0.001
Creatinine (μmol/L), mean (SD) 127 (54) 120 (49) 148 (62) <0.001
Sodium (mmol/L), mean (SD) 139 (4) 139 (4) 138 (5) 0.002
Duration of admission, mean (SD) 13 (10) 13 (9) 15 (11) 0.030
SD, standard deviation; SBP, systolic blood pressure, DBP, diastolic blood pressure; BMI, body mass index; NYHA, New York Heart Association Class; LVEF, left ventricle
ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; IQR, interquartile range.
with the selected biomarker (galectin-3, EPO, TNF-𝛼R1a, TGF-𝛽)
levels <10th percentile could be classified as ‘high likelihood’ for
the absence of an event, whereas the clinical risk model with
NT-proBNP predicted a low likelihood for the absence of an
event in these patients; in other words, we could potentially and
adequately reclassify these patients by considering the low value
of the biomarker (Table 4). To follow up on this reclassification,
we calculated continuous NRI and IDI, which, however, showed
insignificant NRIs for single selected biomarkers, likely due in part
to the very low numbers of reclassified patients (Supplemental
Table S7).
Further evaluation of the events: death
Of the 22 (3.7%) patients who died within 30 days, median
biomarker levels of the composite endpoint are displayed in the
Supplementary material online (Table S8). None of these had a
galectin-3, NT-proBNP, TNF𝛼-R1a, or EPO level below the 10th
percentile after discharge. At 180 days 91 (15.4%) patients died;
no patient below the 10th percentile cut-off of galectin-3 died,
while other biomarkers failed to identify several patients who .
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.. endured an event. After 1 year of follow-up, only two patients with
a galectin-3< 10th percentile died out of a total of 131 deaths.
Further evaluation of the events:
rehospitalization owing to heart failure
Rehospitalization owing to HF occurred within 30 days in 32
patients (5.4%). None who were rehospitalized had a galectin-3
value below the 10th percentile cut-off. The composite endpoint
of death and HF rehospitalization occurred 202 times within 1 year
after discharge, and only four endpoints occurred in patients with
a galectin-3< 10th percentile. The rate of HF rehospitalizations
and death occurring in both studies, at 30, 90, and 180 days are
displayed in the Supplementary material online (Table S9).
Validation cohort
Data from 285 patients from the TRIUMPH study was available for
use in the current analyses. This subset of patients had baseline
characteristics, which were comparable to the entire TRIUMPH
cohort (N= 478, data not shown). The mean (SD) age was 72
© 2015 The Authors
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Table 2 Biomarkers stratified by rank, displays the cut-off value, the sensitivity and specificity for the cut-off value and
the exact number of endpoints at 180days in Coordinating Study Evaluating Outcomes of Advising and Counselling in
Heart Failure [COACH; complete list; ranked based upon positive predictive value PPV)]
Biomarker Cut-off value Sensitivity 1 – Specificity PPV HF rehospitalization Death Composite Rank
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Galectin-3, ng/mL <11.8 0.872 0.993 0.983 1 0 1 1
EPO, IU/L <2.7 0.879 0.957 0.900 4 2 6 2
TNF𝛼R1a, ng/mL <1.6 0.888 0.957 0.900 5 2 6 3
TGF-𝛽 ,* ng/mL >104.75 0.886 0.948 0.883 4 3 7 4
PSAP-B, ng/mL <37.0 0.885 0.949 0.883 4 4 7 5
GDF-15, ng/mL <1.5 0.874 0.949 0.883 4 4 7 6
Interleukin 6, ng/mL <3.6 0.889 0.940 0.867 7 1 8 7
Neuropilin ng/mL <5.3 0.89 0.942 0.867 6 3 8 8
cTnI, pg/mL <2.0 0.889 0.944 0.867 4 5 8 9
Mesothelin, ng/mL <19.2 0.885 0.949 0.867 5 5 8 10
Troy, ng/mL <0.5 0.89 0.942 0.867 7 5 8 11
ST-2, ng/mL <0.86 0.887 0.948 0.850 7 5 9 12
ESAM, ng/mL <38.9 0.888 0.935 0.850 7 5 9 13
PIGR-1, ng/mL <297.7 0.852 0.935 0.850 6 6 9 14
Osteopontin, ng/mL <76.1 0.892 0.928 0.833 8 3 10 15
VEGF, ng/mL <13.5 0.892 0.922 0.833 6 4 10 16
Syndecan-1, ng/mL <9.5 0.89 0.928 0.833 9 4 10 17
D-Dimer, μg/mL <0.1 0.927 0.928 0.833 6 5 10 18
RAGE, ng/mL <1.4 0.878 0.920 0.833 6 6 10 19
CRP, μg/mL <1.8 0.895 0.920 0.817 7 5 11 20
Angiogenin,* μg/mL >12013.9 0.895 0.913 0.817 10 5 11 21
NT-proBNP, pg/mL <626.8 0.895 0.915 0.817 6 6 11 22
Pentraxin-3, ng/mL <1.8 0.895 0.899 0.800 8 8 12 23
NRP-1, ng/mL <656.4 0.899 0.906 0.783 5 8 13 24
BNP, pg/mL <95.7 0.904 0.893 0.767 8 7 14 25
Cystatin C, μg/mL <5387.9 0.902 0.899 0.767 7 9 14 26
NGAL, ng/mL <62.8 0.904 0.899 0.767 6 10 14 27
MPO, ng/mL <12.1 0.899 0.899 0.750 10 9 15 28
Periostin, ng/mL <2.6 0.878 0.884 0.733 13 11 16 29
HF, heart failure; CRP, C-reactive protein; cTnI, cardiac troponin I; GDF-15, growth differentiation factor 15; RAGE, receptor for advanced glycation end-products; TNF-𝛼R1a,
tumour necrosis factor alpha receptor 1a; MPO, myeloperoxidase; PIGR-1, polymeric immunoglobulin receptor 1; TGF-𝛽, transforming growth factor-beta; NRP-1, neutropilin
1; NT-proBNP, N-terminal pro-B-type natriuretic peptide; ST-2, suppression of tumorigenicity 2; VEGF, vascular endothelial growth factor; EPO, erythropoietin ; ESAM,
endothelial cell-selective adhesion molecule; NGAL, neutrophil gelatinase-associated lipocalin; BNP, B-type natriuretic peptide; PSAP-B, prosaposin B.
*High levels of these markers are associated with less severe HF, and low levels with severe HF.
(±12) years, and 96 (34%) were female. Median [IQR] NT-proBNP
was 2305 [1205–4871] pg/mL and ejection fraction was 32% .14
The Supplementary material online (Table S10) displays the char-
acteristics of this population. Both derivation and validation HF
cohorts had similar composite event rates with an overall 365-day
event rate of 35%. The distribution of plasma galectin-3 levels in
both trials was also similar (see the Supplementary material online,
Figure S1) and measurements were performed with the same
validated assay. The baseline characteristics of COACH and
TRIUMPH are presented in the Supplementary material online
(Table S11). For both studies we stratified patients regard-
ing their galectin-3 levels (10th percentile), as displayed in the
Supplementary material online (Table S12).
Using the TRIUMPH data set, we further evaluated galectin-3,
NT-proBNP, and cTnI. Galectin-3<10th percentile and
NT-proBNP <10th percentile were, in both cohorts, associated
with absence of 30-day mortality. Positive predictive value was .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. calculated for galectin-3, NT-proBNP, and cTnI and were 0.888,
0.852, and 0.857, respectively (see the Supplementary material
online, Table S13). Logistic regression analysis showed that
galectin-3 adjusted for age and sex was significantly associated
with the absence of an event after 180 days, whereas unadjusted
NT-proBNP and cTnI were non-significant (see the Supplementary
material online, Table S14). The composite endpoint at 180 days
from the derivation and validation cohort are displayed in Figure 2;
where we indicated a consistent cut-off point derived from
COACH, namely 11.8 ng/mL. From both studies we calculated
the event count for galectin-3, NT-proBNP and cTnI (see the
Supplementary material online, Table S15).
Discussion
We set out to identify patients at low risk for death or
HF rehospitalization, using a large set of biomarkers. We
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Table 3 Logistic regression model for absence of death and/or heart failure (HF) rehospitalization at 180 days;
biomarker values presented are the 10th percentile cut off in Coordinating Study Evaluating Outcomes of Advising
and Counselling in Heart Failure (COACH)
Biomarker (<10th percentile) based upon rank Odds ratio 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Galectin-3 20.9 2.86–100 0.003
+Age and sex 19.7 2.70–100 0.003
+Clinical risk model+NT-proBNP 8.1 1.06–50 0.039
EPO 3.0 1.27–7.14 0.013
+Age and sex 2.7 1.14–6.67 0.025
+Clinical risk model+NT-proBNP 1.8 0.95–6.67 0.237
TNF𝛼R1a 2.9 1.19–6.67 0.018
+Age and sex 2.5 1.03–5.88 0.042
+Clinical risk model+NT-proBNP 1.1 0.50–3.23 0.819
TGF-𝛽 2.3 1.04–5.26 0.041
+Age and sex 2.2 0.96–5.00 0.063
Biomarkers (<10th percentile) commonly used in daily practice
NT-proBNP 1.1 0.56–2.27 0.750
cTnI 1.7 0.77–3.69 0.188
CI, confidence interval; NT-proBNP, N-terminal pro-B-type natriuretic peptide; EPO, erythropoietin alpha; TGF-𝛽, transforming growth factor-beta; TNF𝛼R1a, tumour necrosis
factor alpha receptor 1a.
Clinical risk model: age, sex, diastolic blood pressure, pulse pressure, stroke, myocardial infarction, atrial fibrillation, peripheral arterial disease, diabetes, left ventricle ejection
fraction, previous HF hospitalization, sodium, creatinine, duration of admission
demonstrated that out of 29 biomarkers, four biomarkers,
namely galectin-3, EPO, TNF𝛼R1a, and TGF-𝛽 had the best per-
formance to identify patients at low risk for events, at their 10th
percentile cut point. Galectin-3 identified patients that suffered no
30-day or 180-day mortality and no 30-day HF rehospitalizations,
and only one 180-day HF rehospitalization. After correction for
the clinical risk model including NT-proBNP, galectin-3 remained
an independent predictor for the absence of events in the logistic
regression and Cox proportional hazard models.
The primary aim was to compare different biomarkers with
respect to their value to identify patients at low risk. Therefore,
we show data for all biomarkers on top of the clinical risk model
without NT-proBNP. As NT-proBNP is the golden standard of HF
biomarkers, we also show additional data on top of the clinical risk
model with NT-proBNP. Galectin-3 levels, not NT-proBNP levels
(both <10th percentile), showed incremental value on top of the
clinical risk model, and the same was observed when combining
galectin-3, EPO, TNF𝛼R1a and TGF-𝛽 (all <10th percentile). We
performed area under the curve (AUC) analyses with and without
NT-proBNP present in the clinical risk model to better position the
role of biomarkers in assessing low risk. We believe this provides
insights in the value of biomarkers predominantly in the low range.
When we included NT-proBNP in the clinical risk model, no
biomarker (galectin-3 included) was associated with a significant
improvement when assessed by NRI.
Galectin-3, which is a surrogate marker of cardiac remodelling,
demonstrates better prognostic value for short-term low risk
compared with biomarkers that resemble haemodynamic loading
conditions, such as natriuretic peptides. We hypothesize that in
low-risk patients, cardiac remodelling may not (yet) have pro-
gressed to a state associated elevated biomarkers of remodeling, .
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. and these patients may therefore be identified by low galectin-3.
Figure 1 depicts how values of galectin-3 have particular power in
the low-range.
As most risk engines or risk scores have been developed to
identify high-risk patients, from a clinical perspective, there is a
clear need to assess if low risk may be present. Such knowledge
may help to safely discharge patients.
So while this may have obvious clinical utility, one should realize
that when selecting a cut point for optimal biomarker decision
making, the conflict between executing a safe discharge must be
balanced with the predicted value of a longer hospital stay or
additional intervention. Further, the challenge, when optimizing
a cut point to sensitivity for adverse events is that, because
of the consequent deterioration in specificity, the population of
candidates may become so small as to be clinically useless. It is
for this rationale that we selected the 10th percentile as optimal
cut point, with a high specificity but with a reasonable number of
patients with such low values. This implies that a subset of HF
patients exists that can be prospectively identified for safe early
discharge. Alternatively, a clinician could be less strict and allow
an event rate of 5–10%, resulting in a higher percentile of patients
who will be classified as low risk, but simultaneously accept a higher
incidence of events. However, the consequence of optimizing safety
at a predefined cost of low numbers of patients and subsequent
events limits the power in statistical analyses (absolute number of
reclassification events is low).
We thus acknowledge the limitation that is intrinsic to the
(small) number of patients in the 10th percentile. Therefore, we
explored other cut points at the 20th and 30th percentiles, and
noted that TNF𝛼R1a, EPO and galectin-3 remained one of the
best biomarkers in predicting low risk. The chosen cut point can
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Figure 1 Adjusted logistic regression analysis for the absence of events in Coordinating Study Evaluating Outcomes of Advising and
Counselling in Heart Failure (COACH) within 180 days for the selected biomarkers across the complete range of percentiles (5th–95th). cTnI,
cardiac troponin I; EPO, erythropoietin alpha; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TGF-B, transforming growth factor-𝛽;
TNF, tumour necrosis factor
be increased depending on the event rate that is accepted by the
caregiver.
We identified several markers that appear helpful in identify-
ing patients at low risk, representing several pathophysiological
domains of heart failure that include inflammation, fibrosis, and
anaemia. For low-risk detection, a cut-off of 1.6 ng/mL of TNF𝛼R1a
was associated with no deaths and only one HF rehospitalization
after 30 days. TNF𝛼R1a is involved in cardiac inflammation, which
is considered an important mechanism contributing to the symp-
toms and progression of HF. Clinically, plasma levels of TNF𝛼R1a
are correlated with the severity of congestive HF and are asso-
ciated with increased risk for incident HF.25 TGF-𝛽 is linked to
fibrosis, and therefore not cardiac specific. This may imply that the
fibrotic response—as a generic response to injury—might reflect
accumulative tissue damage in the HF syndrome. The median
TGF-𝛽 levels in acute HF patients are lower compared with healthy
subjects and may thus reflect impaired repair mechanisms.26 High
(protective) levels of TGF-𝛽 were associated with three and seven
deaths at, respectively, 30 days and 180 days follow-up. Galectin-3
is also related to tissue fibrosis.27 It has been shown to predict
short-term mortality and HF rehospitalization17,28–31 and might .
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.. be of potential value in patients with HF with preserved ejection
fraction.32,33 Galectin-3 recently received Class IIb American
College of Cardiology/American Heart Association guideline
recommendation as additive for risk stratification.34
Another symptom that is prevalent in HF is anaemia. Erythro-
poietin alpha, which is produced by the kidneys, promotes the
proliferation and differentiation of erythroid progenitor cells and is
highly expressed under stress and hypoxic35 conditions, including
HF.36. It also identified a low rate of HF readmissions throughout
the complete follow-up, and no patients with an EPO below the
10th percentile died within 90 days of follow-up. Interestingly, both
inflammatory and fibrotic biomarkers were present in the top four
biomarkers that provided best prediction of low risk. This
underscores a potential role for inflammation and fibrosis
formation in the period after AHF.
We further validated the main results from galectin-3,
NT-proBNP, and cTnI in an independent validation cohort,
also of patients admitted to the hospital with AHF, and observed
a similar pattern to that in the derivation cohort.
The prognostic importance of dynamics of (or change in)
NT-proBNP during hospitalization have been studied in seven
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Table 4 Patients were initially stratified by the clinical risk model+NT-proBNP into tertiles. The right columns depict
the actual number of events of patients with low biomarker levels (<10th percentile), validating the clinical score
Tertiles of odds ratios as calculated by the clinical risk
model+NT-proBNP for the absence of an event
Number of events
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Biomarkers <10th
percentile (n= 60/group)
OR <4.3,
‘High risk’
OR 4.4–8.4,
‘Intermediate risk’
OR >8.5
‘Low risk’
OR <4.3 OR 4.4–8.4 OR >8.5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Galectin-3 12% 18% 70% 1 0 0
EPO 17% 33% 50% 2 2 1
TNF𝛼-R1a 17% 17% 66% 2 1 3
TGF-𝛽 30% 27% 43% 3 1 2
OR, odds ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; EPO, erythropoietin alpha; TGF-𝛽, transforming growth factor-beta; TNF𝛼R1a, tumour necrosis factor
alpha receptor 1a.
Percentages indicate the proportion of patients with low biomarker level that are in each tertile of the clinical risk model: age, sex, diastolic blood pressure, pulse pressure,
stroke, myocardial infarction, atrial fibrillation, peripheral arterial disease, diabetes, left ventricle ejection fraction, previous HF hospitalization, sodium, creatinine, duration of
admission+NT-proBNP.
(acute) HF cohorts, together comprising 1301 patients, in the
European collaboration on acute decompensated heart failure
(ÉLAN-HF).37 The study has shown that changes in NT-proBNP
during hospitalization improve the prediction of future events. We
only had discharge NT-proBNP values and, although discharge lev-
els have better prognostic value than admission levels,38,39 we thus
could not look at changes in NT-proBNP. Further, our clinical
risk model differed from ÉLAN-HF: both models included age,
sodium, blood pressure, New York Heart Association (NYHA)
functional class, but we used creatinine and ÉLAN-HF urea, and we
entered sex, left ventricular ejection fraction (LVEF), diabetes, pulse
pressure, stroke, myocardial infarction, atrial fibrillation, peripheral
arterial disease, previous HF hospitalization, duration of admission,
and NT-proBNP, while ÉLAN-HF entered peripheral oedema. But
most importantly, ELAN-HF focused on high risk and did not specif-
ically address low-risk assessment. In our analyses, we chose to
base our clinical risk model on the published risk model, namely
the COACH risk engine. Although it includes several established
prognostic factors, this risk engine does not include all known
prognostic factors, such as the presence of anaemia, left bun-
dle branch block, and HF medication. Inclusion of these variables
might potentially have altered the performance of the biomarkers
within the multivariable analyses. From our data, we conclude that
NT-proBNP might be a better predictor for high risk in acute HF
than it is for low risk—an observation that has beenmade before.40
Our data might be of help in daily care for HF patients. In
clinical practice, NT-proBNP is the gold standard for estimat-
ing the prognosis of HF patients. In our dataset however, as
demonstrated by logistic regression analysis (Table 3), NT-proBNP
(<10th percentile) was not significantly associated with the
absence of death and/or HF rehospitalization. Our data therefore
questions whether NT-proBNP is the ideal marker for assessing
low risk in semi-acute HF patients, although at present the aggre-
gate data for risk assessment in HF are clearly supporting a central
role for natriuretic peptides. The use of biomarkers may help
to decide whether to safely discharge hospitalized patients with
low risk, as indicated by these markers. Knowledge of risk status .
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. may also allow personalization of their follow-up schedule. For
example, whereas high-risk patients may benefit from more fre-
quent and immediate post-discharge monitoring, low-risk patients
could be identified as requiring lower intensity post-discharge
resource utilization. Reclassification of patients based upon low
biomarker levels may be helpful in reducing the burden of frequent
hospital visits, but clinicians should always be aware of other signs
and symptoms that could help avoid incorrect reclassification.
The advantage of our analysis is that by selecting an outcome
by the lowest 10th percentage of a certain biomarker in the total
HF population it is more plausible for clinical use. As the current
national 30-day HF rehospitalization rate in the USA exceeds
25%, a strategy considering galectin-3 levels may represent a more
precise and objective identification of discharge candidates than
existing tools.
Strengths and limitations
Our analysis has several limitations. As a substudy of the original
COACH and TRIUMPH trials, our conclusions should be limited
to that of generating a hypothesis. Further, many of the assays we
evaluated are only available as research tools, and additional assays
could not be performed in COACH given the limited volume
of sample per patient. In addition, most biomarkers were mea-
sured on a multiple platform. Importantly, in COACH, no clinical
decision-making was based upon marker levels, such that our find-
ings must be prospectively validated before being applied clinically.
Other limitations include that we cannot make statements
about the dynamics of biomarkers, and it has been reported that
changes of, for example galectin-341–44 and NT-proBNP37,45 con-
fer additional prognostic importance. Further, all patients stud-
ied were hospitalized and sample collection took place before
discharge. Thus, these findings cannot be applied to emergency
department disposition decision-making without further evalu-
ation. Finally, in the validation cohort (TRIUMPH trial), only
galectin-3, NT-proBNP, and cTnI were available.
The strengths of the study are the pre-specified adjudicated
end point assessment, the pre-specified biomarker substudies,
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Figure 2 Galectin-3 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for composite endpoint at 180 days in the derivation and
validation cohort. (a) Derivation cohort [Coordinating Study Evaluating Outcomes of Advising and Counselling in Heart Failure (COACH)].
(b) Validation cohort (Translational Initiative on Unique and novel strategies for Management of Patients with Heart Failure (TRIUMPH)).
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and a very large set of biomarkers. Further, we could validate
the results of our initial observations in a completely indepen-
dent cohort, with almost identical outcomes. Thus, our results
do suggest that biomarker testing may enable the identification
of a cohort of potential candidates for early hospital discharge
in selected low-risk HF patients. As the impact and timing of
post-discharge is controversial,46,47 an objective determinate (i.e.
a biomarker level) may assist in the proper use of these resources.
Our approach could help in identifying patients that would ben-
efit from early follow-up visits or could be monitored less
frequently.
Conclusion
Most clinically available biomarkers have been assessed for their
ability to identify patients at high risk of adverse events. We
show data that suggest that biomarkers can be used to assess
low risk. Out of a large panel of 29 biomarkers, galectin-3, EPO,
TNF𝛼R1a, and TGF-𝛽 emerged as predictors for low risk, while
the routine biomarkers NT-proBNP and cTnI did not. Galectin-3
remained significantly associated with low risk after adjustment for
the clinical risk model with NT-proBNP. Future studies are needed
to prospectively validate our findings, as biomarkers indicating
low risk may be helpful to identify patients that can be safely
discharged or do not need short-term revision in the outpatient
clinic.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Distribution of galectin-3 in the derivation (COACH)
and validation (TRIUMPH) cohort.
Table S1. The intra- and inter-assay coefficients of variation of the
biomarkers.
Table S2. Counts of death, HF rehospitalization and composite end
point based upon the 10th percentile for all biomarkers at 30 days,
90 days, 180 days, and 1 year.
Table S3. ‘Top 4’ biomarker rank (based upon number of events);
shown for different Cut off values (10th, 20th, and 30th per-
centiles).
Table S4. Ranking of biomarkers based upon the frequency they
were added to the model after multiple (×1000) bootstrap runs
where all the biomarkers and variables of the clinical risk model
were entered in a stepwise backward logistic regression analysis
for the absence of an event.
Table S5. Cox regression model for death and/or HF rehospital-
ization at 180 days; biomarker values presented are the 10th per-
centile cut off in COACH.
Table S6. Receiver operating characteristic upon the addition
of different biomarkers based upon the 10th percentile for HF
rehospitalisation and fatal event at 180 days in COACH.
Table S7. The reclassification indices; NRI continuous and IDI at
180 days.
Table S8. Biomarker levels of patients who endured a composite
event at 30 days and 180 days, or not (COACH). ..
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.. Table S9. Count of HF rehospitalization and death occurring in both
studies at 30, 90, 180, and 365 days.
Table S10. Baseline characteristics—validation cohort (TRI-
UMPH).
Table S11. Baseline characteristics of the COACH and TRIUMPH
studies.
Table S12. Baseline characteristics stratified by galectin-3 level for
COACH and TRIUMPH.
Table S14 Logistic regression model for absence of death and/or
HF rehospitalization at 180 days; biomarker values presented are
the 10th percentile cut off in TRIUMPH.
Table S15. Counts of HF rehospitalization and all-cause mortality
across both studies at different time-points.
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